Drug intelligence / Profile preview

NuViana CD3

Development stage: Unknown
Lead developer: Sanix Formulation
Modality: Small Molecules
Administration: Oral

Overview

**NuViana CD3** is an oral multi-ingredient nutritional and nutraceutical formulation containing calcium carbonate, alpha-lipoic acid, benfotiamine, inositol, chromium picolinate, pyridoxine hydrochloride, folic acid, methylcobalamin, and vitamin D3. The formulation combines B-vitamin and vitamin D supplementation, calcium replacement, antioxidant support from alpha-lipoic acid, and metabolic nutrient support. It is listed in the neuro product portfolio of Sanix Formulation's website, which currently identifies the operating company as Aviana Formulation.

Brand names: NuViana CD3
Other names: calcium carbonate + alpha-lipoic acid + benfotiamine + inositol + chromium picolinate + pyridoxine hydrochloride + folic acid + methylcobalamin + vitamin D3

Beyond the preview

Go deeper on NuViana CD3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuViana CD3.

Explore the full profile